Can NogoA Be a Suitable Target to Treat Ischemic Stroke?  

作　　者：Suliman Khan Abdul Nasir 

机构地区：[1]Medical Research Center,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou,540014,China

出　　处：《Neuroscience Bulletin》2024年第4期557-560,共4页神经科学通报（英文版）

基　　金：supported by the Science and Technology Developmental Plan of Henan Province,China(232102520025);The National Foreign Expert Program of China(QN2022026001L).

摘　　要：Treating stroke or restoring brain function after stroke remains challenging for clinicians[1,2].Researchers have largely focused on developing neuroprotective strategies and translating these discoveries from rodent experiments to the clinical setting;however,these have been typified by several failures[2].It is known that astrocytes play a crucial role in the pathogenesis of ischemic stroke[3,4].They are activated in response to stimuli arising from injury,characterized by drastic changes to their morphology and function-associated gene expression.Reactive astrocytes exacerbate secondary neurodegeneration(repair of nervous tissue by the generation of new neurons,glial cells,axons,myelin,or synapses)[5]as well as provide neuroprotection during CNS pathologies[6].It is worth noting that myelin-related neurite growth inhibitors induce the suppression of axon regeneration after stroke[7].

关 键 词：protective NogoA CLINICAL 

分 类 号：R743.3[医药卫生—神经病学与精神病学]